Publications by authors named "B B Polonsky"
Background: There are limited data on clinical and arrhythmic outcomes after a first ventricular tachyarrhythmia (VTA) in heart failure (HF) patients who receive a primary prevention implantable cardioverter-defibrillator (ICD).
Objective: This study was designed to quantify the burden of and to identify risk factors for recurrent VTA in this population and to evaluate the risk of all-cause mortality associated with recurrent VTA.
Methods: The study comprised 789 patients who experienced VTA following primary prevention ICD implantation in 5 ICD trials (MADIT-II, MADIT-RISK, MADIT-CRT, MADIT-RIT, RAID).
Risk stratification for ventricular tachyarrhythmia in patients with nonischemic cardiomyopathy.
J Cardiovasc Electrophysiol
January 2025
Introduction: The implantable cardioverter defibrillator reduces mortality among patients with heart failure (HF) due to ischemic heart disease. Clinical trial data have called into question the benefit of an ICD in patients with HF due to nonischemic cardiomyopathy (NICM). We developed a risk stratification score for ventricular tachyarrhythmia (VTA) among patients with NICM receiving a primary prevention ICD.
View Article and Find Full Text PDFBackground And Aims: Long QT syndrome (LQTS) and coronary artery disease (CAD) are both associated with increased risk of ventricular tachyarrhythmia However, there are limited data on the incremental risk conferred by CAD in adult patients with congenital LQTS. We aimed to investigate the risk associated with CAD and life threatening events (LTEs) in patients with LQTS after age 40 years.
Methods: The risk of LTEs (comprising aborted cardiac arrest, sudden cardiac death, or appropriate defibrillator shock) from age 40 through 75 years was examined in 1,020 subjects from the Rochester LQTS registry, categorized to CAD ( = 137) or no-CAD ( = 883) subgroups.
Digoxin and Risk of Ventricular Tachyarrhythmia and Death in ICD Recipients.
JACC Clin Electrophysiol
July 2024
Article Synopsis
- Some studies indicate that digoxin may lead to adverse health outcomes, including higher mortality rates in heart failure patients.
- This study aimed to determine if digoxin increases the risk of ventricular tachycardia (VT) or ventricular fibrillation (VF) in heart failure patients with implantable cardioverter-defibrillators (ICDs).
- The results showed that digoxin use significantly raised the risk of VT/VF by 48%, increased the risk of death by 37%, and led to more ICD shocks, highlighting potential dangers of digoxin in this patient group.
Article Synopsis
- This study analyzed sex differences in life-threatening heart conditions (ventricular tachycardia and ventricular fibrillation) among patients with implantable cardioverter-defibrillators (ICDs) who had previously experienced these issues.
- Results showed that women had a significantly lower risk of these events and death compared to men, as well as a reduced risk of recurrent VT/VF.
- Additionally, racial disparities were noted, with White women showing a much lower risk compared to White men, while Black women had similar risks to Black men.